Cargando…

Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family

Case series Patient: — Final Diagnosis: PRKAG2 syndrome Symptoms: Palpitation • dyspnea and fatigue • syncope Medication: — Clinical Procedure: Radiofrequency catheter ablation • pacemaker implantion • antiarrhythmic drugs Specialty: Cardiology OBJECTIVE: Rare disease BACKGROUND: PRKAG2 syndrome dia...

Descripción completa

Detalles Bibliográficos
Autores principales: de Paula van der Steld, Lenises, Campuzano, Oscar, Pérez-Serra, Alexandra, de Barros Zamorano, Mabel Moura, Matos, Selma Sousa, Brugada, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518846/
https://www.ncbi.nlm.nih.gov/pubmed/28690312
http://dx.doi.org/10.12659/AJCR.904613
_version_ 1783251542497820672
author de Paula van der Steld, Lenises
Campuzano, Oscar
Pérez-Serra, Alexandra
de Barros Zamorano, Mabel Moura
Matos, Selma Sousa
Brugada, Ramon
author_facet de Paula van der Steld, Lenises
Campuzano, Oscar
Pérez-Serra, Alexandra
de Barros Zamorano, Mabel Moura
Matos, Selma Sousa
Brugada, Ramon
author_sort de Paula van der Steld, Lenises
collection PubMed
description Case series Patient: — Final Diagnosis: PRKAG2 syndrome Symptoms: Palpitation • dyspnea and fatigue • syncope Medication: — Clinical Procedure: Radiofrequency catheter ablation • pacemaker implantion • antiarrhythmic drugs Specialty: Cardiology OBJECTIVE: Rare disease BACKGROUND: PRKAG2 syndrome diagnosis is already well-defined as Wolff-Parkinson-White syndrome (WPW), ventricular hypertrophy (VH) due to glycogen accumulation, and conduction system disease (CSD). Because of its rarity, there is a lack of literature focused on the treatment. The present study aimed to describe appropriate strategies for the treatment of affected family members with PRKAG2 syndrome with a long follow-up period. CASE REPORT: We studied 60 selected individuals from 84 family members (32 males, 53.3%) (mean age 27±16 years). Patients with WPW and/or VH were placed in a group of 18 individuals, in which 11 (61.1%) had VH and WPW, 6 (33.3%) had isolated WPW, and 1 (5.6%) had isolated VH. Palpitations occurred in 16 patients (88.9%), chest pain in 11 (61.1%), dizziness in 13 (72.2%), syncope in 15 (83.3%), and dyspnea in 13 (72%). Sudden cardiac death (SCD) occurred in 2 (11.1%), and 2 patients with cardiac arrest (CA) had asystole and pre-excited atrial flutter-fibrillation (AFL and AF) as the documented mechanism. Transient ischemic attack (TIA) and learning/language disabilities with delayed development were observed. Genetic analysis identified a new missense pathogenic variant (p.K290I) in the PRKAG2 gene. Cardiac histopathology demonstrated the predominance of vacuoles containing glycogen derivative and fibrosis. The treatment was based on hypertension and diabetes mellitus (DM) control, antiarrhythmic drugs (AD), anticoagulation, and radiofrequency catheter ablation (RCA). Six patients (33.3%) underwent pacemaker implantation (PM). CONCLUSIONS: The present study describes the clinical treatment for a rare cardiac syndrome caused by a PRKAG2 mutation.
format Online
Article
Text
id pubmed-5518846
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher International Scientific Literature, Inc.
record_format MEDLINE/PubMed
spelling pubmed-55188462017-08-02 Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family de Paula van der Steld, Lenises Campuzano, Oscar Pérez-Serra, Alexandra de Barros Zamorano, Mabel Moura Matos, Selma Sousa Brugada, Ramon Am J Case Rep Articles Case series Patient: — Final Diagnosis: PRKAG2 syndrome Symptoms: Palpitation • dyspnea and fatigue • syncope Medication: — Clinical Procedure: Radiofrequency catheter ablation • pacemaker implantion • antiarrhythmic drugs Specialty: Cardiology OBJECTIVE: Rare disease BACKGROUND: PRKAG2 syndrome diagnosis is already well-defined as Wolff-Parkinson-White syndrome (WPW), ventricular hypertrophy (VH) due to glycogen accumulation, and conduction system disease (CSD). Because of its rarity, there is a lack of literature focused on the treatment. The present study aimed to describe appropriate strategies for the treatment of affected family members with PRKAG2 syndrome with a long follow-up period. CASE REPORT: We studied 60 selected individuals from 84 family members (32 males, 53.3%) (mean age 27±16 years). Patients with WPW and/or VH were placed in a group of 18 individuals, in which 11 (61.1%) had VH and WPW, 6 (33.3%) had isolated WPW, and 1 (5.6%) had isolated VH. Palpitations occurred in 16 patients (88.9%), chest pain in 11 (61.1%), dizziness in 13 (72.2%), syncope in 15 (83.3%), and dyspnea in 13 (72%). Sudden cardiac death (SCD) occurred in 2 (11.1%), and 2 patients with cardiac arrest (CA) had asystole and pre-excited atrial flutter-fibrillation (AFL and AF) as the documented mechanism. Transient ischemic attack (TIA) and learning/language disabilities with delayed development were observed. Genetic analysis identified a new missense pathogenic variant (p.K290I) in the PRKAG2 gene. Cardiac histopathology demonstrated the predominance of vacuoles containing glycogen derivative and fibrosis. The treatment was based on hypertension and diabetes mellitus (DM) control, antiarrhythmic drugs (AD), anticoagulation, and radiofrequency catheter ablation (RCA). Six patients (33.3%) underwent pacemaker implantation (PM). CONCLUSIONS: The present study describes the clinical treatment for a rare cardiac syndrome caused by a PRKAG2 mutation. International Scientific Literature, Inc. 2017-07-10 /pmc/articles/PMC5518846/ /pubmed/28690312 http://dx.doi.org/10.12659/AJCR.904613 Text en © Am J Case Rep, 2017 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) )
spellingShingle Articles
de Paula van der Steld, Lenises
Campuzano, Oscar
Pérez-Serra, Alexandra
de Barros Zamorano, Mabel Moura
Matos, Selma Sousa
Brugada, Ramon
Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family
title Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family
title_full Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family
title_fullStr Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family
title_full_unstemmed Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family
title_short Wolff-Parkinson-White Syndrome with Ventricular Hypertrophy in a Brazilian Family
title_sort wolff-parkinson-white syndrome with ventricular hypertrophy in a brazilian family
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5518846/
https://www.ncbi.nlm.nih.gov/pubmed/28690312
http://dx.doi.org/10.12659/AJCR.904613
work_keys_str_mv AT depaulavandersteldlenises wolffparkinsonwhitesyndromewithventricularhypertrophyinabrazilianfamily
AT campuzanooscar wolffparkinsonwhitesyndromewithventricularhypertrophyinabrazilianfamily
AT perezserraalexandra wolffparkinsonwhitesyndromewithventricularhypertrophyinabrazilianfamily
AT debarroszamoranomabelmoura wolffparkinsonwhitesyndromewithventricularhypertrophyinabrazilianfamily
AT matosselmasousa wolffparkinsonwhitesyndromewithventricularhypertrophyinabrazilianfamily
AT brugadaramon wolffparkinsonwhitesyndromewithventricularhypertrophyinabrazilianfamily